Mission Bio, Inc. Raises $10M Series A
Single-cell DNA analysis company Mission Bio, Inc. announced it has secured $10 million in Series A funding led by Mayfield Fund.
Mission Bio’s Tapestri platform is a scalable, highly sensitive, and customizable precision genomics platform that addresses current industry shortcomings with throughput up to 10,000 cells and DNA accessibility at the single-cell level. This allows researchers and clinicians to identify with unprecedented scale and sensitivity the important differences among cells within a patient sample that may impact disease progression and treatment.
“We are excited to partner with Charlie, Adam, and the Mission Bio team. We believe their technology and expertise will play a transformative role in delivering on the promise of precision medicine,” said Ursheet Parikh of Mayfield Fund. “With their unique approach combining precision engineering with cutting-edge biochemistry, we see the opportunity to greatly impact the economics and success of the development and clinical use of precision therapies.”
The funding will be used to support the launch of its Tapestri platform.